2024-01-22 18:34:33 ET
Summary
- Cellectis is a biotech company focused on developing allogeneic CAR T-cell therapy, which uses donor T cells instead of the patient's own cells.
- They have three main projects in clinical studies, with their most advanced therapy being outlicensed to Allogene.
- The company has an unproven, promising tech with a long developmental lag time, making this something I'm not ready to recommend at this time.
Topline Summary
Read the full article on Seeking Alpha
For further details see:
Cellectis: Pushing A Different Kind Of CAR-T Up The Hill